BEDFORD, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) — Spryte Medical, a pioneer in intravascular neuro imaging, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the INSYTE pivotal trial. The trial will evaluate the safety and effectiveness of Spryte’s neuro Optical Coherence Tomography (nOCT) imaging system for use during intracranial aneurysm treatment procedures.
Author: Ken Dropiewski
Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure
MONTREAL, Nov. 19, 2025 /PRNewswire/ – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced…
Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips’ leadership in precision diagnostics in neurology
November 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an extended partnership with Cortechs.ai, a pioneer in quantitative neuroimaging solutions. Together, the companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems [1], empowering clinicians with faster, more objective, and reproducible insights into brain health. The collaboration strengthens Philips’ leadership in precision neuro diagnostics, combining Philips’ next-generation MR technologies with Cortechs.ai’s AI-driven quantitative neuro imaging post processing software [1] to transform how neurological diseases are detected, monitored, and managed.Combining complementary expertise for smarter brain imagingUp to 25% [2] of all MR procedures are brain scans, and radiology departments face growing demand amid increasing staff shortages. At the same time, the number of patients with neurological conditions such as Alzheimer’s disease, multiple sclerosis (MS), and brain tumors continue to rise globally. Current MR interpretation of neurodegenerative diseases or neuro oncology cases depends heavily on visual assessment, introducing variability and requiring significant expertise and time in an already overloaded system.Through this extended partnership, Philips and Cortechs.ai aim to deliver more standardized and data-driven imaging. By integrating quantitative analysis tools such as brain volumetrics, lesion quantification, and tumor tracking directly into the Philips MR imaging workflow [1], clinicians gain objective, numerical data alongside images – enabling faster, more consistent, and confident diagnoses.Empowering clinicians with precision and speedThe integration of Cortechs.ai’s NeuroQuant® solutions for Alzheimer’s, MS and brain tumors within Philips’ Smart Reading environment – a cloud-based AI platform that combines imaging, reading, and reporting directly on the MR systems [1] – marks a major step toward precision neuroimaging.With this integration, clinicians can automatically receive AI-generated quantitative reports within their standard MR workflow on the MR system or PACS, without adding extra steps for technologists. The zero-click process ensures quality-checked data and standardized outputs, helping radiologists interpret brain scans more objectively, faster and with greater confidence.“By extending our partnership with Cortechs.ai, we are accelerating the transition to fully quantitative, AI-powered neuroimaging,” said Ioannis Panagiotelis, PhD, Business Leader, MRI, Philips. “This integration brings precision, reproducibility, and efficiency to neurological MR, helping clinicians make faster, more confident decisions for patients living with complex brain conditions.”Driving productivity and improving care through AIPhilips is driving productivity and improving care through deep AI integration that tackles some of healthcare’s most pressing challenges – from workforce shortages to the growing demand for advanced diagnostics. By automatically generating quantitative reports within existing workflows, AI helps radiologists save time, improve consistency, and boost throughput. Objective numerical biomarkers enhance diagnostic accuracy, enabling more reproducible assessments and confident comparisons across time and sites. And by minimizing manual post-processing through automated, quality-controlled workflows, technologists can focus more on what matters most – delivering a better, more personalized patient experience.“Cortechs.ai’s mission has always been to empower clinicians with actionable, quantitative insights,” said Kyle Frye, Chief Executive Officer, Cortechs.ai. “By combining our advanced neuro analytics with Philips’ leading MR platform and AI infrastructure, we’re making it easier to personalize brain care and track neurological changes with precision.”Setting a new standard in precision neuro diagnosticsCortechs.ai’s NeuroQuant® solutions are already available on Philips Advanced Visualization Workspace. With this extended partnership, Philips reinforces its commitment to advancing the field of neurology – empowering healthcare providers to deliver better care for more people, in less time, with greater confidence.
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled “Treatment of Liver Metastases from […]
RapidAI Earns FDA Clearance for Rapid Aortic, Bringing AI-Driven Aortic Measurements and Surveillance to Care Teams
SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the pioneer of deep clinical AI and global leader in enterprise imaging, today announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI solution designed to transform the acute assessment and longitudinal management of aortic disease. […]
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch of the TriNav® XP Infusion System, the latest advancement in the company’s portfolio of pressure-enabled drug delivery systems designed to improve […]
VenstraMedical Secures Investment From Highcroft Capital to Advance Next-generation Cardiac Support Device
NEWCASTLE, Australia & EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–VenstraMedical, a cardiovascular medical device company, today announced an investment from Highcroft Capital, a Minnesota-based venture capital firm specializing in MedTech innovation. The funding will accelerate development of VenstraMedical’s next-generation percutaneous ventricular assist device (pVAD) — a low-profile, full-flow system designed to provide complete […]
VahatiCor Closes Oversubscribed Series B Financing to Accelerate A-FLUX® Development for Coronary Microvascular Dysfunction.
The new capital will advance the SERRA-I early feasibility study, engineering development, and preparation for additional studies on coronary microvascular dysfunction. SANTA CLARA, Calif.–(BUSINESS WIRE)–VahatiCor, a medtech company transforming cardiac care for Coronary Microvascular Dysfunction (CMD), today announced the successful closing of its $23 million Series B financing led by S3 […]
CryoTherapeutics partners with SpectraWAVE and CRF to Launch ICECAP: A First-of-its-Kind Clinical Study Targeting Non-Obstructive High-Risk Coronary Plaques with Cryotherapy and Advanced Intravascular Imaging
LIÈGE, Belgium & BEDFORD, Mass.–(BUSINESS WIRE)–CryoTherapeutics, a medical device company developing minimally invasive localized cryotherapy for the treatment of coronary artery disease, today announced a unique three-way collaboration with SpectraWAVE, an innovator in intravascular imaging and physiology and the Cardiovascular Research Foundation (CRF), the global leader in cardiovascular research, to […]
Catheter Precision Announces Third VIVO Installation in France
First-ever multi-year agreement highlights commitment to French electrophysiology market First-ever multi-year agreement highlights commitment to French electrophysiology market



